SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
GreenLight Biosciences Holdings (GRNA) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+3572.8%).
- Analyst consensus target $11.00 (+3572.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 38/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GRNA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio6.19
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.27
Book Value / Share$0.00
Revenue / Share$0.05
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$11.00 (+3572.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.30 |
$3M |
$-28.97M |
-965.2% |
| 2020 |
$-0.56 |
$962K |
$-54.28M |
-5642.3% |
| 2021 |
$-0.93 |
$0.00 |
$-114.73M |
- |
| 2022 |
$-1.27 |
$6.38M |
$-167.06M |
-2616.8% |
